Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers W Sakai, EM Swisher, BY Karlan, MK Agarwal, J Higgins, C Friedman, ... Nature 451 (7182), 1116-1120, 2008 | 1193 | 2008 |
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells M Taniai, A Grambihler, H Higuchi, N Werneburg, SF Bronk, DJ Farrugia, ... Cancer research 64 (10), 3517-3524, 2004 | 272 | 2004 |
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants K Wu, SR Hinson, A Ohashi, D Farrugia, P Wendt, SV Tavtigian, ... Cancer research 65 (2), 417-426, 2005 | 161 | 2005 |
Functional assays for classification of BRCA2 variants of uncertain significance DJ Farrugia, MK Agarwal, VS Pankratz, AM Deffenbaugh, D Pruss, C Frye, ... Cancer research 68 (9), 3523-3531, 2008 | 134 | 2008 |
Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint AB D'Assoro, R Busby, K Suino, E Delva, GJ Almodovar-Mercado, ... Oncogene 23 (23), 4068-4075, 2004 | 87 | 2004 |
Low Estrogen Receptor (ER)–positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease? A Landmann, DJ Farrugia, L Zhu, EJ Diego, RR Johnson, A Soran, ... American journal of clinical pathology 150 (1), 34-42, 2018 | 71 | 2018 |
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? PK Lovelock, AB Spurdle, MTS Mok, DJ Farrugia, SR Lakhani, S Healey, ... Breast Cancer Research 9, 1-13, 2007 | 71 | 2007 |
Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity LC Walker, PJ Whiley, FJ Couch, DJ Farrugia, S Healey, DM Eccles, F Lin, ... Human mutation 31 (6), E1484-E1505, 2010 | 64 | 2010 |
Impaired p53 function leads to centrosome amplification, acquired ERα phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts AB D'assoro, R Busby, ID Acu, C Quatraro, MM Reinholz, DJ Farrugia, ... Oncogene 27 (28), 3901-3911, 2008 | 42 | 2008 |
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors DJ Farrugia, A Landmann, L Zhu, EJ Diego, RR Johnson, M Bonaventura, ... Modern Pathology 30 (8), 1078-1085, 2017 | 41 | 2017 |
Improved breast cancer care quality metrics after implementation of a standardized tumor board documentation template DJ Farrugia, TD Fischer, D Delitto, LRP Spiguel, CM Shaw Journal of oncology practice 11 (5), 421-423, 2015 | 33 | 2015 |
Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial? BJ Gebhardt, J Thomas, ZD Horne, CE Champ, DJ Farrugia, E Diego, ... Advances in Radiation Oncology 3 (3), 258-264, 2018 | 11 | 2018 |
HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors? A Landmann, DJ Farrugia, E Diego, M Bonaventura, A Soran, R Johnson, ... Journal of Clinical Oncology 34 (15_suppl), 612-612, 2016 | 5 | 2016 |
Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer BZ Clark, DJ Farrugia, A Landmann, EJ Diego, DJ Dabbs, SL Puhalla, ... American Journal of Clinical Pathology 149 (4), 332-343, 2018 | 2 | 2018 |
Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER-disease? A Landmann, DJ Farrugia, E Diego, A Soran, R Johnson, M Bonaventura, ... Journal of Clinical Oncology 34 (15_suppl), 580-580, 2016 | 2 | 2016 |
Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy. DJ Farrugia, A Landmann, E Diego, PF McAuliffe, R Johnson, ... Journal of Clinical Oncology 34 (15_suppl), e23265-e23265, 2016 | 1 | 2016 |
Macrocephaly and developmental delay caused by missense variants in RAB5C K Koop, W Yuan, F Tessadori, WR Rodriguez-Polanco, J Grubbs, ... Human molecular genetics 32 (21), 3063-3077, 2023 | | 2023 |
High Ki-67 is associated with an increased likelihood of a pathologic complete response in patients with estrogen receptor positive breast cancer JS Lee, EJ Diego, A Soran, DJ Farrugia, A Landmann, M Bonaventura, ... ANNALS OF SURGICAL ONCOLOGY 24, 50-51, 2017 | | 2017 |
Abstract P6-09-14: Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer DJ Farrugia, A Landmann, PF McAuliffe, EJ Diego, R Johnson, ... Cancer Research 77 (4_Supplement), P6-09-14-P6-09-14, 2017 | | 2017 |
Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer DJ Farrugia, A Landmann, PF McAuliffe, EJ Diego, R Johnson, ... CANCER RESEARCH 77, 2017 | | 2017 |